A Challenge for Society, Primary Care and the Individual Patient to Curb the Obesity Epidemic and Malnutrition

Gregory Gasic, PhD

A woman’s bare feet standing on a scale, highlighting the obesity epidemic and malnutrition.

A November 14, 2024 article in the New York times by Nina Agrawal entitled “Three-Quarters of U.S. Adults Are Now Overweight or Obese” that was a commentary on an alarming article in The Lancet, “National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA,1990–2021 and forecast up to 2050” reveals the staggering rise of obesity rates nationwide since 1990. The study convincingly argued that prevailing public policies must address the burgeoning crisis. Major reforms at structure of our society focusing the delivery of healthcare to children, young adults, and promotion of better nutrition at all socioeconomic levels. Individuals need to take an active role in their own well-being, from adopting a healthier diet to engaging in greater levels of exercise. Herein, we will review the important points of this article from definitions to recommendations, how countries with much lower World Health Organization Indices of obesity such as Japan differ, and how early behavioral, nutritional, and pharmacological interventionist are needed. Equally important, individuals must be active participants, using their own agency to combat this epidemic that now represents a a half trillion dollar drain on the USA economy. We will review simple biomarkers of obesity, prediabetes, insulin resistance, metabolic syndrome, and global inflammation in our bodies that correlates with adverse health outcomes that include anxiety and major depression.

Obese Woman Hand Holding Excessive Belly Fat with Measure Tape.

The paper defined “overweight” adults as those who were age 25 and over with a body mass index (BMI) at or over 25 kg/m2, and “obese” adults as those with a BMI at or over 30 kg/m2. Although the BMI is an imperfect measure that falls short of capturing variations in body fat distribution across the population, it is a practical first approximation fat accumulation. The shape of major fat deposits in both men and women also contribute to the to how damaging they are to our health and biomarkers of body-wide pathology.

The authors found a steady increase in the proportion of overweight and obese individuals over the past three decades. The rate of obesity in particular rose sharply in adults between 1990 and 2021 and doubled to more than 40 percent.  Equally alarming, among girls and women aged 15 to 24 the rate of obesity nearly tripled to 29 percent.

Beyond the economic implications found by the 2024 Joint Economic Committee Republicans (JEC Republicans) estimated that obesity causes an “average of $5,155 in average excess medical costs per affected person corresponding to $520 billion in total excess healthcare costs in 2023 alone”. Over the next 10 years, obese individuals will result in $8.2 to $9.1 trillion in excess medical expenditures. These costs will result in lost productivity and labor supplies that will translate in lost tax revenues. Obesity increases the likelihood of numerous metabolic symptoms and their associated complications: high blood pressure, Type 2 diabetes, liver disease, kidney disease, heart attack and stroke. Acting via global body inflammation, obesity is correlated with infertility, cancer and increases in anxiety and major depression. High maternal BMI’s often translate to high BMI’s for their children.

Fortunately, we are experiencing an increase in our understanding of the physiology of hunger and its genetic, physiological, and environmental underpinnings. Amongst the environmental contributors are high caloric ultra processed foods, poor access to fresh fruits and vegetables, and increased sedentary activity. Unlike Japan with much lower rates of obesity, we lack walkable, fast and clean reliable public transport and cars are mere extensions of ourselves.

Bariatric Surgery and Glucagon-like peptide 1 (GLP-1 Receptor agonists like Wegovy,  Zepbound, and Mounjaro, whose mechanism of action involves mimicking a natural hormone in the body called GLP-1 will be needed. They stimulate insulin production from the pancreas, reduce liver sugar production, and slow down digestion. These agents are effective obesity treatments to augment lifestyle changes. To have a public health impact, these drugs will have to be affordable, and more research will be needed to determine how to tapper them without a rebound of weight. Moreover, individuals will need to adhere to healthy nutrition habits (e.g. Mediterranean diet) for the health benefits to be manifest.

Society’s Role and Chile’s Example of How to Promote Healthy Nutrition

Healthy food and Unhealthy Food.

To impact the diets of individuals will require major structural changes in nutrition that must be coordinated at the federal level to bolster regulatory changes at the local and state levels. These must include subsidies for healthy foods and taxes on sugar-sweetened beverages and cereals. More government regulation of the nutritional content in foods, and marketing of unhealthy foods is clearly needed. In a February 7, 2018, New York Times Article (In Sweeping War on Obesity, Chile Slays Tony the Tiger), Andrew Jacobs cites how in Chile’s “New regulations, which corporate interests delayed for almost a decade, require explicit labeling and limit the marketing of sugary foods to children”.

Another 2024 article (Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population representative studies with 222 million children, adolescents, and adults) in The Lancet concluded that the “combined burden of underweight and obesity has increased in most countries, driven by an increase in obesity, while underweight and thinness remain prevalent in south Asia and parts of Africa. A healthy nutrition transition that enhances access to nutritious foods is needed to address the remaining burden of underweight while curbing and reversing the increase in obesity.”

Biomarkers for Metabolic Syndrome, Insulin Resistance and Global Inflammation

Metabolic Syndrome write on a paperwork with keywords isolated.

Your yearly primary care exam should include a Lipid Panel, Hemoglobin A1c (% glycated hemoglobin is directly related to the concentration of blood glucose during the previous 3 months; and a high sensitivity Reactive C protein level (hsRCP; normal levels are 0.3-1.0mg/dL) that will provide biomarkers to as the first indicators of disease risk. Metabolic syndrome (MS) is a cluster of conditions (increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels) that elevate your risk of heart disease, stroke and type 2 diabetes. Cordero et al., 2008, 2009 published that:” Triglyceride (TG) to high-density lipoprotein (HDL) ratio values >2.75 in men and >1.65 in women were found in the MS in Active Subjects (MESYAS) study -18,778 active workers enrolled in 3 insurance companies in Spain- to be highly predictive of the MS diagnosis.” The TG/HDL ratio was highly predictive of a first coronary event regardless of body mass index (BMI). Therefore, the TG/HDL ratio is an important surrogate marker that needs to be highlighted in your lipid panel. Diet and exercise can have beneficial effects on this ratio as well as on the % of HbA1c.

Measures of the hsRPC levels indicate an acute infection that causes inflammation or a metabolic condition that elevates body inflammation and raises this marker in the blood beyond the normal level, 0.3-1.0mg/dL. The hsCRPlevels are predictive of cardiovascular disease especially if baseline low density lipoprotein cholesterol (LDL) is above 130mg/dL. Statin treatment will lower hsCRP and modify disease risk. Diet and regular exercise will also modify this marker of cardiovascular risk.

obesity epidemic and malnutrition

References and Links:

  1. GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050. Lancet. 2024 Dec 7;404(10469):2278-2298. doi: 10.1016/S0140-6736(24)01548-4. Epub 2024 Nov 14. PMID: 39551059; PMCID: PMC11694015
  2. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023 Jul;20(7):463-474. doi: 10.1038/s41569-023-00849-3. Epub 2023 Mar 28. PMID: 36977782.
  3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29. PMID: 38432237; PMCID: PMC7615769.
  4. Cordero A, Laclaustra M, León M, Casasnovas JA, Grima A, Luengo E, Ordoñez B, Bergua C, Bes M, Pascual I, Alegría E; MESYAS Registry Investigators. Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol. 2008 Aug 15;102(4):424-8. doi: 10.1016/j.amjcard.2008.03.079. PMID: 18678299.
  5. Cordero A, Andrés E, Ordoñez B, León M, Laclaustra M, Grima A, Luengo E, Moreno J, Bes M, Pascual I, Civeira F, Pocoví M, Alegría E, Casasnovas JA; Metabolic Syndrome Active Subjects Study Investigators. Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol. 2009 Nov 15;104(10):1393-7. doi: 10.1016/j.amjcard.2009.07.008. PMID: 19892056.
  6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43. doi: 10.1056/NEJM200003233421202. PMID: 10733371.
  7. Lin GM, Liu K, Colangelo LA, Lakoski SG, Tracy RP, Greenland P. Low-Density Lipoprotein Cholesterol Concentrations and Association of High-Sensitivity C-Reactive Protein Concentrations With Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016 Jan 1;183(1):46-52. doi: 10.1093/aje/kwv144. Epub 2015 Nov 22. PMID: 26597828; PMCID: PMC4690475.

VMeDx Virtual Medical Assistant Your Healthcare Companion

With VMeDx Virtual Medical Assistant, experience a smarter way to handle healthcare tasks, providing accurate information and seamless communication in one tool.

VMeDx virtual medical assistant woman smiling with hands on the pocket